Kevin Puylaert Biography and Net Worth

SVP, Chief Sales Officer of SOPHiA GENETICS

Kevin Puylaert is the Chief Sales Officer at SOPHiA GENETICS. He joined the company in March 2016. With a passion for innovation and a drive to bring solutions to healthcare professionals around the world, Kevin leads the company’s efforts to accelerate the global adoption of the SOPHiA DDM™ Platform.

With his industry expertise and entrepreneurial spirit, Kevin has been instrumental in the growth of SOPHiA GENETICS, driving the company’s global expansion through his expertise in developing and executing successful business strategies.

Under his leadership, Kevin spearheaded the company’s expansion outside of Europe for the first time, successfully introducing SOPHiA GENETICS to APAC, LATAM and the US, and launched the company’s Boston office, serving as General Manager for several years before returning to Europe to lead Business Development and then serving as Managing Director for EMEA.

With a background in science and business, Kevin holds a Master’s degree in science from the Louvain School of Management, Belgium, and a Bachelor’s degree in business engineering from the University of Leuven, Belgium.

What is Kevin Puylaert's net worth?: The estimated net worth of Kevin Puylaert is at least $773.59 thousand as of April 20th, 2026. Mr. Puylaert owns 148,197 shares of SOPHiA GENETICS stock worth more than $773,588 as of May 1st. This net worth approximation does not reflect any other assets that Mr. Puylaert may own. Learn More about Kevin Puylaert's net worth.
How do I contact Kevin Puylaert?: The corporate mailing address for Mr. Puylaert and other SOPHiA GENETICS executives is , , . SOPHiA GENETICS can also be reached via phone at 41-21-694-1060. Learn More on Kevin Puylaert's contact information.
Has Kevin Puylaert been buying or selling shares of SOPHiA GENETICS?: During the last quarter, Kevin Puylaert has sold $3,200.28 in shares of SOPHiA GENETICS stock. Most recently, Kevin Puylaert sold 33 shares of the business's stock in a transaction on Monday, April 20th. The shares were sold at an average price of $5.08, for a transaction totalling $167.64. Following the completion of the sale, the insider now directly owns 148,197 shares of the company's stock, valued at $752,840.76. Learn More on Kevin Puylaert's trading history.
Are insiders buying or selling shares of SOPHiA GENETICS?: In the last twelve months, insiders at the sold shares 57 times. They sold a total of 193,859 shares worth more than $943,777.03. The most recent insider tranaction occured on April, 27th when insider Philippe Menu sold 5,000 shares worth more than $24,100.00. Insiders at SOPHiA GENETICS own 4.9% of the company. Learn More about insider trades at SOPHiA GENETICS.
Information on this page was last updated on 4/27/2026.

Kevin Puylaert Insider Trading History at SOPHiA GENETICS

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
4/20/2026	Sell	33	$5.08	$167.64	148,197
4/6/2026	Sell	624	$4.86	$3,032.64	148,230
3/19/2026	Sell	33	$4.76	$157.08	92,386

Kevin Puylaert Buying and Selling Activity at SOPHiA GENETICS

SOPHiA GENETICS Company Overview

SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific. SOPHiA GENETICS SA was incorporated in 2011 and is headquartered in Rolle, Switzerland.

Today's Range

Now: $5.29

$5.26

$5.36

50 Day Range

MA: $4.81

$4.10

$5.28

2 Week Range

Now: $5.29

$2.59

$5.70

Volume

723 shs

Average Volume

170,656 shs

Market Capitalization

$361.97 million

P/E Ratio

N/A

Dividend Yield